[go: up one dir, main page]

MX2010005629A - Preparacion farmaceutica para tratamiento de hiperplasia prostatica benigna. - Google Patents

Preparacion farmaceutica para tratamiento de hiperplasia prostatica benigna.

Info

Publication number
MX2010005629A
MX2010005629A MX2010005629A MX2010005629A MX2010005629A MX 2010005629 A MX2010005629 A MX 2010005629A MX 2010005629 A MX2010005629 A MX 2010005629A MX 2010005629 A MX2010005629 A MX 2010005629A MX 2010005629 A MX2010005629 A MX 2010005629A
Authority
MX
Mexico
Prior art keywords
pharmaceutical preparation
benign prostatic
prostatic hyperplasia
treating benign
protease
Prior art date
Application number
MX2010005629A
Other languages
English (en)
Inventor
Lucia Desser
Bernhard Lotz
Thomas Mohr
Original Assignee
Volopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volopharm Gmbh filed Critical Volopharm Gmbh
Publication of MX2010005629A publication Critical patent/MX2010005629A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere al uso de por lo menos una proteasa para la fabricación de un medicamento para el tratamiento y/o prevención de la hiperplasia/hipertrofia prostática benigna, en donde el medicamento se adapta para la administración enteral, por lo menos una proteasa se selecciona el grupo que consiste de proteasas de planta, animales no mamíferos y microbios y por lo menos una proteasa se administra en una cantidad de 1 a 100 mg/kg de peso corporal.
MX2010005629A 2007-12-03 2008-12-03 Preparacion farmaceutica para tratamiento de hiperplasia prostatica benigna. MX2010005629A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0196207A AT506095A1 (de) 2007-12-03 2007-12-03 Verwendung von proteasen
PCT/AT2008/000428 WO2009070818A1 (en) 2007-12-03 2008-12-03 Pharmaceutical preparation for treating benign prostatic hyperplasia

Publications (1)

Publication Number Publication Date
MX2010005629A true MX2010005629A (es) 2010-08-18

Family

ID=40404976

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005629A MX2010005629A (es) 2007-12-03 2008-12-03 Preparacion farmaceutica para tratamiento de hiperplasia prostatica benigna.

Country Status (11)

Country Link
US (1) US8231870B2 (es)
EP (2) EP2559439B1 (es)
JP (1) JP2011505385A (es)
AT (1) AT506095A1 (es)
CA (1) CA2705986C (es)
DK (1) DK2559439T3 (es)
ES (1) ES2528348T3 (es)
MX (1) MX2010005629A (es)
PL (1) PL2559439T3 (es)
RU (1) RU2485971C2 (es)
WO (1) WO2009070818A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI482629B (zh) * 2008-07-01 2015-05-01 Tobishi Pharmaceutical Co 下泌尿道疾病治療劑及下泌尿道症狀改善劑
AU2009290466B2 (en) * 2008-09-10 2014-06-12 Pt. Dexa Medica Composition of thrombolytic agent and anti thrombosis and also its production method
JP6091431B2 (ja) * 2011-01-31 2017-03-15 ルコラス−エム．ディー．リミテッド 医薬的使用
US20140154235A1 (en) 2011-05-12 2014-06-05 Smith & Nephew Orthopaedics Ag Wound debridement compositions containing seaprose and methods of wound treatment using same
AU2013259360B2 (en) * 2012-05-11 2017-07-13 Smith & Nephew, Inc. Use of Seaprose to remove bacterial biofilm
ITMI20121997A1 (it) * 2012-11-23 2014-05-24 Velleja Res Srl Composizioni fibrinolitiche per la prevenzione e il trattamento degli stati flebotrombotici
ITTO20121050A1 (it) * 2012-12-06 2014-06-07 Giuseppe Carpignoli Sostanze vegetali ad effetto curativo
US10086053B2 (en) 2012-12-06 2018-10-02 Giuseppe CARPIGNOLI Therapeutic vegetable substances
JP6382972B2 (ja) * 2013-10-23 2018-08-29 ジェムバックス アンド カエル カンパニー，リミティド 前立腺肥大治療用及びその予防用の組成物
HUP1400294A2 (hu) 2014-06-13 2015-12-28 Skillpharm Kft Clopidogrel új alkalmazása
ES2938347T3 (es) * 2014-08-25 2023-04-10 Anatara Lifesciences Ltd Formulación antidiarreica que evita la resistencia antimicrobiana
US11628207B2 (en) 2016-07-27 2023-04-18 Smith & Nephew, Inc. Use of thermolysin to reduce or eliminate bacterial biofilms from surfaces
IT201600081379A1 (it) * 2016-08-03 2018-02-03 Neilos S R L Composizione farmaceutica per uso nel trattamento delle patologie prostatiche.
US11413300B2 (en) 2017-01-30 2022-08-16 Smith & Nephew, Inc. Synergistic combination of thermolysin and an antibacterial agent to reduce or eliminate bacterial biofilms from surfaces
JP7207877B2 (ja) * 2018-06-27 2023-01-18 小林製薬株式会社 ナットウキナーゼを含む食品
JP7207878B2 (ja) * 2018-06-27 2023-01-18 小林製薬株式会社 ナットウキナーゼを含む食品

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0456724T3 (da) * 1989-01-27 1995-10-02 Immunolytics Inc Præparat og fremgangsmåde til behandling af benign prostatisk hypertrofi
JPH05229983A (ja) * 1992-02-21 1993-09-07 Sankyo Co Ltd レトロジヒドロカルコン化合物
DE4305460C2 (de) 1993-02-23 1997-09-04 Albert Dr Scheller Pharmazeutische oder kosmetische, Enzyme enthaltende Zubereitung, Verfahren zu deren Herstellung und deren Verwendung
JP3978250B2 (ja) * 1996-08-16 2007-09-19 株式会社フジモト・コーポレーション テストステロン５α−リダクターゼ阻害剤
US20010025059A1 (en) * 2000-01-10 2001-09-27 Kastke Floyd A. Composition and method for treating non-bacterial prostatitis
ZA200002342B (en) 2000-05-12 2001-01-11 Pharmachoice Healthcare Propri Nutritional supplement.
WO2003035688A2 (en) 2001-10-26 2003-05-01 Novartis Pharma Gmbh Targeted thrombosis by tissue factor polypeptides
EP1553974A1 (en) * 2002-09-19 2005-07-20 Cristiano Alberto Ribeiro Santana Pharmaceutical composition comprising carriers for products
LV13161B (en) * 2004-02-16 2005-07-20 Maris Skromanis Proteolytic pharmaceutical composition
US20060024385A1 (en) 2004-07-27 2006-02-02 Pedersen Mark A Metabolic capacity enhancing compositions and methods for use in a mammal
US7758594B2 (en) 2005-05-20 2010-07-20 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
RU2306145C1 (ru) * 2006-03-28 2007-09-20 Олег Викторович Бейдик Средство для лечения хронического простатита

Also Published As

Publication number Publication date
EP2559439B1 (en) 2014-11-26
RU2010127336A (ru) 2012-01-10
WO2009070818A1 (en) 2009-06-11
EP2559439A1 (en) 2013-02-20
US8231870B2 (en) 2012-07-31
US20100254968A1 (en) 2010-10-07
CA2705986A1 (en) 2009-06-11
CA2705986C (en) 2017-06-13
JP2011505385A (ja) 2011-02-24
EP2224948A1 (en) 2010-09-08
AT506095A1 (de) 2009-06-15
RU2485971C2 (ru) 2013-06-27
PL2559439T3 (pl) 2015-04-30
ES2528348T3 (es) 2015-02-09
DK2559439T3 (en) 2014-12-08

Similar Documents

Publication Publication Date Title
MX2010005629A (es) Preparacion farmaceutica para tratamiento de hiperplasia prostatica benigna.
TN2009000137A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2001085212A3 (en) Drug delivery systems for photodynamic therapy
WO2005117954A3 (en) Compositions and methods for treatment of neovascular diseases
DE602007004615D1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
NZ606825A (en) Methods and compositions for treating complement-associated disorders
MX2010014233A (es) Compuestos quimicos 251.
TW200615266A (en) Organic compounds
MY143795A (en) Tetrahydropyridoindole derivatives
WO2009129509A3 (en) Methods and compositions for treating post-operative pain comprising a local anesthetic
UA92907C2 (uk) Похідні тетрагідроіндазолону
EA200800798A1 (ru) Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
WO2008024978A3 (en) Tetrahydroindolone and tetrahydroindazolone derivatives
PH12013500938A1 (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200602328A (en) Quinazoline derivatives
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
MY157790A (en) Trazodone composition for once a day administration
NZ597060A (en) Composition for the treatment of benign prostate hyperplasia comprisin degarelix
DE602007011975D1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
SE0950392L (sv) Sammansättning för behandling av hudåkommor
EP1503748A4 (en) DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY
RU2007138867A (ru) Режимы дозирования транс-кломифена
WO2007130501A3 (en) Combination therapy for treatment of cancer

Legal Events

Date Code Title Description
FG Grant or registration